Literature DB >> 2439786

Effect of bisoprolol on exercise tolerance in patients with coronary heart disease: placebo-controlled double-blind crossover study.

K Schnellbacher, E Marsovszky, H Roskamm.   

Abstract

Twelve patients with stable angina pectoris due to coronary heart disease received single oral doses of 5, 10, and 20 mg bisoprolol in a placebo-controlled double-blind crossover study. A significant, dose-related increase in exercise tolerance in symptom-limited bicycle exercise tests performed 2.5 h after administration (p less than 0.05) was demonstrated. The dose-effect relationship was especially marked in reduction of heart rate, rate-pressure product, and ischemic ST-segment depression at the highest comparable workload (p less than 0.01). Compared with placebo, mean improvements in work performance (determined by the maximal workload attained, i.e., W X minutes) increased to 105% with 5 mg, to 122% with 10 mg, and to 131% with 20 mg bisoprolol. The lower incidence rate of exercise-induced symptoms of angina pectoris at an identical workload was marked at the 10- and 20-mg dose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2439786     DOI: 10.1097/00005344-198511001-00026

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.

Authors:  M S Dixon; P Thomas; D J Sheridan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

3.  Hemodynamic evaluation of bisoprolol after coronary artery surgery in patients with altered left ventricular function.

Authors:  M Goldstein; J L Vincent; J L Le Clerc; A d'Hollander; C Melot; R J Kahn
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.